Anticancer agent 298 

Anticancer agent 298 is a bi-nuclear Cu(II)-hydrazone complexe. Anticancer agent 298 can bind to the CDK-2 active site (PDB ID: 3IG7) via hydrogen bonds with key amino acid residues. Anticancer agent 298 exerts cytotoxic effects against hepatocellular carcinoma cells, and has lower cytotoxicity against normal human embryonic kidney cells. Anticancer agent 298 can be used for the research of hepatocellular carcinoma^[1].

Anticancer agent 298 (Compound 2) potently inhibits hepatocellular carcinoma (HepG-2) cells with an IC₅₀ of 12.27 μM and has an IC₅₀ of 90.16 μM against normal human embryonic kidney (HEK-2) cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1049.75

C₃₆H₅₄Br₂Cu₂N₆O₁₂

CC(C1=C(O[Cu]2([OH]CC)([OH]CC)([OH]CC)Br)C=C(O[Cu]3([OH]CC)([OH]CC)([OH]CC)Br)C(C(C)=[N]3/N=C/C4=CC=CC([N+]([O-])=O)=C4)=C1)=[N]2/N=C/C5=CC([N+]([O-])=O)=CC=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Samy F, et al. Tailoring, spectroscopic, DFT, solvatochromic, antitumor, and molecular docking studies of new polynuclear Cu(II)-hydrazone complexes. Sci Rep. 2026;16(1):795. Published 2026 Jan 6.  [Content Brief]